Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 756 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: End-stage Renal Disease Clear all
Not listed Phase 2Phase 3 Interventional

Frequent Hemodialysis Network: Nocturnal Trial

NCT00271999
View directory record Official record
Conditions
End Stage Renal Disease, Hemodialysis
Interventions
Nocturnal home hemodialysis
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2010 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Using Shared Decision Making to Improve Kidney Transplantation Rates

NCT06141499
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Failure
Interventions
Provider educational materials, Patient letters
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Disparities in National Kidney Allocation Policy

NCT02879812
View directory record Official record
Conditions
Kidney Disorders
Interventions
Performance Feedback Reports, Educational Video for Staff, Educational Video for Patients, Educational Webinar, Standard Care, United Network for Organ Sharing (UNOS) Pamphlet
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
56,332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 10, 2026, 2:12 PM EDT
Enrolling by invitation Not applicable Interventional

Xeltis Hemodialysis Access Graft (aXess) US Study

NCT06494631
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Xeltis Hemodialysis Access (aXess) graft
Device
Lead sponsor
Xeltis
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
7
States / cities
Phoenix, Arizona • Tuscon, Arizona • Sarasota, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed No phase listed Observational

VIRTUUS Children's Study

NCT03719339
View directory record Official record
Conditions
Renal Transplant Rejection, Pediatric Kidney Disease, End Stage Renal Disease, Nephropathy, BK Virus (Nephropathy), Antibody-mediated Rejection, Acute Cellular Graft Rejection
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Years to 18 Years
Enrollment
445 participants
Timeline
2017 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Desensitization of Renal Transplant Candidates

NCT00298883
View directory record Official record
Conditions
End Stage Renal Disease, Kidney Transplantation
Interventions
Myfortic
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2012 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Effects of Lowering Dialysate Calcium Level on Progression of Coronary Artery Calcification and Bone Histomorphometry

NCT00297219
View directory record Official record
Conditions
End-Stage Renal Disease, Hemodialysis
Interventions
Low dialysate calcium, high dialysate calcium
Drug
Lead sponsor
Ege University
Other
Eligibility
18 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 4, 2009 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03963895
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB002 Dose 1, AB002 Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 10, 2026, 2:12 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma

NCT05287945
View directory record Official record
Conditions
Carcinoma, Renal Cell
Interventions
Orellanine
Drug
Lead sponsor
Oncorena AB
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients

NCT00477516
View directory record Official record
Conditions
End-Stage Renal Disease
Interventions
exposure to a high-calcium dialysate bath
Procedure
Lead sponsor
James B. Wetmore, MD
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2012 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional

Volume,Sodium and Blood Pressure Management in HD

NCT01766882
View directory record Official record
Conditions
End Stage Renal Failure
Interventions
Lower sodium intervention, Progressive Challenge to Post Dialysis Weight
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Ann Arbor, Michigan • Livonia, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 2Phase 3 Interventional

Myfortic vs. Cellcept in Kidney Transplant Recipients

NCT00533624
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Mycophenolate Sodium Delayed Release Tablets, Mycophenolate Mofetil
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

NCT01473420
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease
Interventions
Epoetin Hospira, Epogen Amgen
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
73
States / cities
Azusa, California • Bakersfield, California • Long Beach, California + 51 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 10, 2026, 2:12 PM EDT
Not yet recruiting Not applicable Interventional

Dry Weight Reduction Intervention Via Extra Ultrafiltration

NCT07637110
View directory record Official record
Conditions
Fluid Accumulation, Blood Pressure Management, End Stage Renal Disease (ESRD)
Interventions
Ultrafiltration
Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Avacopan in Participants With Normal Renal Function and Participants With End-Stage Renal Disease (ESRD)

NCT06468826
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Avacopan
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Miami Lakes, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Nefecon in Patients With Primary IgA (Immunoglobulin A) Nephropathy

NCT03643965
View directory record Official record
Conditions
Primary IgA Nephropathy
Interventions
Nefecon, Placebo oral capsule
Drug
Lead sponsor
Calliditas Therapeutics AB
Industry
Eligibility
18 Years and older
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
34
States / cities
Birmingham, Alabama • Tucson, Arizona • Palo Alto, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2024 · Synced Oct 10, 2026, 2:12 PM EDT
Active, not recruiting Phase 4 Interventional

One-month Latent Tuberculosis Treatment for Renal Transplant Candidates

NCT05411744
View directory record Official record
Conditions
Latent Tuberculosis, End Stage Renal Disease, Renal Transplant Candidate for Right Kidney, Renal Transplant Candidate for Left Kidney
Interventions
1 month Rifapentine, Isoniazid and Vitamin B6
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 90 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Not applicable Interventional Results available

Clinical Evaluation of a Vascular Venous Anastomotic Connector [InterGraft VIG-only Study]

NCT02532621
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Venous InterGraft Connector, sutured arterial anastomosis of an implanted vascular graft for hemodialysis, hemodialysis
Device · Procedure
Lead sponsor
Phraxis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
10
States / cities
Dothan, Alabama • Cartersville, Georgia • Macon, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

NCT00317694
View directory record Official record
Conditions
Chronic Kidney Failure
Interventions
Fermagate, Placebo
Drug
Lead sponsor
Ineos Healthcare Limited
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2009 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 3 Interventional Results available

Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis

NCT00597753
View directory record Official record
Conditions
Chronic Renal Failure, Chronic Kidney Disease, Anemia
Interventions
peginesatide, Epoetin Alfa
Drug
Lead sponsor
Affymax
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
89
States / cities
Paragould, Arkansas • Fairfield, California • Granada Hills, California + 76 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 10, 2026, 2:12 PM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers

Protein Supplementation in Dialysis Patients

NCT00367198
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Pro-Stat
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 75 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

NCT02581124
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
JTZ-951, Lapatinib
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2a Study To Evaluate The Pharmacokinetics, Safety, Efficacy, Tolerability, And Pharmacodynamics of Sotatercept (ACE-011) for the Correction of Anemia in Subjects With End-stage Renal Disease on Hemodialysis.

NCT01146574
View directory record Official record
Conditions
Anemia
Interventions
Sotatercept, Placebo
Biological
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
24
States / cities
Azusa, California • Glendale, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2024 · Synced Oct 10, 2026, 2:12 PM EDT
Completed Phase 1 Interventional

SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney Disease

NCT06283589
View directory record Official record
Conditions
Calciphylaxis
Interventions
INZ-701
Drug
Lead sponsor
Inozyme Pharma
Industry
Eligibility
18 Years to 69 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Coral Springs, Florida • Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 10, 2026, 2:12 PM EDT